Mercado de diagnóstico de cáncer de próstata en Oriente Medio y África, por tipo de producto (instrumentos, reactivos y consumibles y accesorios), tipo de diagnóstico (pruebas de detección preliminares, pruebas de confirmación), grupo de edad (adultos, niños y geriatría), tipo (adenocarcinoma de próstata, carcinoma de células pequeñas y otros), estadio (cáncer de próstata localizado, cáncer de próstata recurrente/avanzado y cáncer de próstata resistente a la castración (metastásico y no metastásico)), tipo de muestra (sangre, tejido, orina y otros), usuario final (laboratorios de diagnóstico independientes, hospitales, institutos de investigación del cáncer, clínicas, centros quirúrgicos ambulatorios y otros), canal de distribución (licitación directa, ventas minoristas), país (Sudáfrica, Arabia Saudita, Emiratos Árabes Unidos, Egipto, Israel y resto de Oriente Medio y África) Tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado: mercado de diagnóstico del cáncer de próstata en Oriente Medio y África
Se espera que el mercado de diagnóstico de cáncer de próstata gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 12,9% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 320,40 millones para 2028. El aumento del enfoque en la carga de la enfermedad y la creciente conciencia sobre la enfermedad son los principales impulsores que impulsan el mercado de diagnóstico de cáncer de próstata en el período de pronóstico.
El cáncer de próstata comienza cuando las células de la glándula prostática comienzan a crecer a un ritmo anormal y la afección se conoce como cáncer de próstata. La próstata es una glándula que se encuentra únicamente en los hombres y que produce parte del líquido que forma parte del semen. El diagnóstico del cáncer de próstata es una técnica de detección del cáncer principalmente en la etapa temprana para llevar a cabo un futuro enfoque de tratamiento que pueda aumentar la tasa de supervivencia.
The development of prostate cancer is closely linked with the age, with the increasing geriatric population, there is the significant increase in the incidence for prostate cancer. This will increase the demand for the diagnostics product for the detection of the disease and is expected to act as a driver for the prostate cancer diagnostics market. The PSA testing is one of the primary tests that are used for prostate cancer detection. However, the contradictions between the government and medical services provider for using PSA and related test is expected to restraint the prostate cancer diagnostics market. The market have a huge potential to grow and with the entry of new market players trying to enter market using business expansion via distribution agreements and have invested towards the prostate cancer diagnosis is expected to increase the market size and will act as opportunity for the prostate cancer diagnostics market. The barrier related with conducting the cancer diagnostics test may affect the life of the population and this is one of the most difficult part to overcome with respect to the low income countries, thus this is affecting the diagnostics community and acting as a challenge for the prostate cancer diagnostics market.
The prostate cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the prostate cancer diagnostics market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Prostate Cancer Diagnostics Market Scope and Market Size
The prostate cancer diagnostics market is categorized into eight notable segments which are based on the product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product type, the prostate cancer diagnostics market is segmented into instruments, reagents & consumables and accessories. In 2021, reagents & consumables segment is dominating in the prostate cancer diagnostics market as it includes the PSA testing products which is the primary test recommended for preliminary testing.
- Según el tipo de diagnóstico, el mercado de diagnóstico del cáncer de próstata se segmenta en pruebas de detección preliminares y pruebas confirmatorias. En 2021, el segmento de pruebas de detección preliminares domina el mercado de diagnóstico del cáncer de próstata, ya que la cantidad de pruebas preliminares supera la cantidad de pruebas confirmatorias en un porcentaje significativo.
- Según el grupo de edad, el mercado de diagnóstico del cáncer de próstata se segmenta en adultos, pediátricos y geriátricos. En 2021, el segmento geriátrico domina el mercado de diagnóstico del cáncer de próstata, ya que alrededor del 60 % de los casos se diagnostican en hombres mayores de 65 años.
- Según el tipo, el mercado de diagnóstico del cáncer de próstata se segmenta en adenocarcinoma de próstata, carcinoma de células pequeñas y otros. En 2021, el segmento de adenocarcinoma de próstata domina el mercado de diagnóstico del cáncer de próstata porque más del 95 por ciento de los cánceres de próstata son adenocarcinomas que se desarrollan en las células glandulares y la línea de la glándula prostática.
- En función de la etapa, el mercado de diagnóstico del cáncer de próstata se segmenta en cáncer de próstata localizado, cáncer de próstata recurrente/avanzado y cáncer de próstata resistente a la castración (metastásico y no metastásico). En 2021, el segmento de cáncer de próstata localizado domina el mercado de diagnóstico del cáncer de próstata, ya que aproximadamente entre el 80 y el 85 por ciento de todos los cánceres de próstata se detectan en las etapas locales o regionales que representan las etapas I, II y III.
- Según el tipo de muestra, el mercado de diagnóstico del cáncer de próstata se segmenta en sangre, tejido, orina y otros. En 2021, el segmento de sangre domina el mercado de diagnóstico del cáncer de próstata, ya que la sangre es la muestra principal para la prueba preliminar más común, que es la prueba de PSA, y debido a la fácil disponibilidad de sangre, el procedimiento menos complejo de recolección de muestras de sangre no requiere mucho tiempo, lo que se espera que domine el mercado de diagnóstico del cáncer de próstata.
- En función de los usuarios finales, el mercado de diagnóstico del cáncer de próstata se segmenta en laboratorios de diagnóstico independientes, hospitales, institutos de investigación del cáncer, clínicas, centros quirúrgicos ambulatorios y otros. En 2021, el segmento de laboratorios de diagnóstico independientes domina el mercado de diagnóstico del cáncer de próstata, ya que el segmento está especializado en la realización de diversos diagnósticos de cáncer de próstata.
- Según el canal de distribución, el mercado de diagnóstico del cáncer de próstata se segmenta en licitación directa y ventas minoristas. En 2021, el segmento de licitación directa domina el mercado de diagnóstico del cáncer de próstata, ya que es la principal fuente de adquisición de reactivos, consumibles, dispositivos y accesorios por parte de las organizaciones de atención médica y los laboratorios de diagnóstico.
Análisis a nivel de país del mercado de diagnóstico de cáncer de próstata
Se analiza el mercado de diagnóstico de cáncer de próstata y se proporciona información sobre el tamaño del mercado por país, tipo de producto, tipo de diagnóstico, grupo de edad, tipo, etapa, tipo de muestra, usuarios finales y canal de distribución como se menciona anteriormente.
Los países cubiertos en el informe del mercado de diagnóstico de cáncer de próstata son Sudáfrica, Arabia Saudita, Emiratos Árabes Unidos, Egipto, Israel y el resto de Medio Oriente y África.
Se espera que Sudáfrica crezca en el período de pronóstico de 2021 a 2028 debido al creciente enfoque en los productos de diagnóstico del cáncer de próstata y la creciente conciencia al respecto.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.
Las iniciativas estratégicas de los fabricantes están creando nuevas oportunidades para los actores del mercado de diagnóstico del cáncer de próstata
El mercado de diagnóstico de cáncer de próstata también le proporciona un análisis detallado del mercado para cada país: el crecimiento en las ventas de productos de diagnóstico de cáncer de próstata, el impacto de los avances en el diagnóstico de cáncer de próstata y los cambios en los escenarios regulatorios con su apoyo al mercado de diagnóstico de cáncer de próstata. Los datos están disponibles para el período histórico de 2010 a 2019.
Análisis del panorama competitivo y de la cuota de mercado de los diagnósticos de cáncer de próstata
El panorama competitivo del mercado de diagnóstico del cáncer de próstata proporciona detalles por competidor. Los detalles incluidos son la descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y amplitud de los productos, el dominio de las aplicaciones y la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado de diagnóstico del cáncer de próstata.
Las principales empresas que ofrecen servicios de diagnóstico de cáncer de próstata son F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc., HUMASIS, Teco Diagnostics, Hologic Inc., Accuquik Test Kits, MDxHealthcare, Abbott, Siemens Healthcare GmbH, OPKO Health Inc., Myraid Genetics, Inc., DiaSorin SpA, Beckman Coulter, Inc. (una subsidiaria de Danaher), Genomic Health, Inc. (una subsidiaria de Exact Sciences Corporation), bioMérieux SA, Metamark Genetics, Inc., Prostatype Genomics, Fujirebio, Proteomedix, Eurolyser Diagnostica GmbH, entre otros actores nacionales. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Numerosos lanzamientos de productos y acuerdos son también iniciados por empresas de todo el mundo que también están acelerando el mercado del diagnóstico del cáncer de próstata.
Por ejemplo,
- En enero de 2021, Hologic Inc. anunció que había acordado adquirir SOMATEX, Inc. por 64 millones de dólares. Esta empresa es proveedora de biomarcadores para el cáncer. Tras la adquisición completa, Hologic Inc. dará un impulso en el mercado mundial de biomarcadores oncológicos y ampliará la cartera de productos de la empresa para pacientes con cáncer, lo que aumentará las ventas e ingresos futuros de la empresa.
- En agosto de 2020, HUMASIS anunció que había aprobado el examen preliminar para cotizar en la Bolsa de Valores de Corea el mes pasado después de someterse a un proceso de evaluación técnica por parte de una agencia de evaluación profesional en noviembre del año pasado y pronto recibirá la aprobación para cotizar en la bolsa de valores de Corea. Esto será un logro para la empresa y la impulsará en la expansión comercial y las estrategias comerciales futuras.
La colaboración, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de diagnóstico del cáncer de próstata, lo que también proporciona el beneficio para que la organización mejore su oferta para el mercado de diagnóstico del cáncer de próstata.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USERS COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EPIDEMIOLOGY
5 COMPARATIVE ANALYSIS WITH PARENT MARKET
6 REGULATORY FRAMEWORK: MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET
6.1 REGULATORY SCENARIO IN THE U.S.
6.2 REGULATORY SCENARIO IN EUROPEAN UNION
6.3 REGULATORY SCENARIO IN JAPAN
6.4 REGULATORY SCENARIO IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF PROSTATE CANCER
7.1.2 INCREASE RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTIC
7.1.3 INCREASE IN GERIATRIC POPULATION
7.1.4 LAUNCH OF NEW PRODUCTS FOR PROSTATE CANCER DIAGNOSTIC
7.1.5 DISEASE CAUSING PROSTATE CANCER
7.2 RESTRAINTS
7.2.1 CONTROVERSY RELATED TO PSA TESTING
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE
7.2.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.3 OPPORTUNITIES
7.3.1 RISING INVESTMENT AND FUNDING BY EMERGING PLAYERS
7.3.2 REIMBURSEMENT POLICY FOR PROSTATE CANCER DIAGNOSIS
7.3.3 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS
7.3.4 RISING SURVIVAL RATE DUE TO EARLY DIAGNOSIS OF PROSTATE CANCER
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY REQUIREMENT FOR DIAGNOSTIC PRODUCTS
7.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTICS TESTS
7.4.3 INACCURATE DIAGNOSIS RESULTS
8 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION BY MANUFACTURERS MADE DURING COVID-19 PANDEMIC
8.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.6 CONCLUSION
9 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 REAGENTS & CONSUMABLES
9.3 INSTRUMENTS
9.4 ACCESSORIES
10 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE
10.1 OVERVIEW
10.2 PRELIMINARY SCREENING TESTS
10.2.1 PROSTATE-SPECIFIC ANTIGEN (PSA) TEST
10.2.2 DIGITAL RECTAL EXAM (DRE) TEST
10.3 CONFIRMATORY TESTS
10.3.1 PCA3 TEST
10.3.2 BIOPSY
10.3.3 IMAGING TESTS
10.3.3.1 ULTRASOUND
10.3.3.2 MAGNETIC RESONANCE IMAGING (MRI)
10.3.3.2.1 MULTIPARAMETRIC MRI
10.3.3.2.2 MRI FUSION-GUIDED PROSTATE BIOPSY
10.3.3.3 CT SCAN
10.3.3.4 BONE SCAN
10.3.3.5 PET/CT SCAN
10.3.4 BIOMARKER
10.3.4.1 RNA BIOMARKERS
10.3.4.2 DNA BIOMARKERS
10.3.4.3 PROTEIN BIOMARKERS
11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE
11.1 OVERVIEW
11.2 PROSTATIC ADENOCARCINOMA
11.3 SMALL CELL CARCINOMA
11.4 OTHERS
12 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP
12.1 OVERVIEW
12.2 GERIATRICS
12.3 ADULT
12.4 PEDIATRIC
13 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE
13.1 OVERVIEW
13.2 LOCALIZED PROSTATE CANCER
13.3 RECURRENT/ADVANCED PROSTATE CANCER
13.4 CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC)
14 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE
14.1 OVERVIEW
14.2 BLOOD
14.3 TISSUE
14.4 URINE
14.5 OTHERS
15 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS
15.1 OVERVIEW
15.2 INDEPENDENT DIAGNOSTIC LABORATORIES
15.3 HOSPITALS
15.4 CLINICS
15.5 AMBULATORY SURGICAL CENTERS
15.6 CANCER RESEARCH INSTITUTES
15.7 OTHERS
16 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
17 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
17.1 MIDDLE EAST & AFRICA
17.1.1 SOUTH AFRICA
17.1.2 SAUDI ARABIA
17.1.3 UAE
17.1.4 ISRAEL
17.1.5 EGYPT
17.1.6 REST OF MIDDLE EAST & AFRICA
18 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
19 SWOT
20 COMPANY PROFILE
20.1 F. HOFFMANN-LA ROCHE LTD
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLI0
20.1.5 RECENT DEVELOPMENTS
20.2 ABBOTT
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 SIEMENS HEALTHCARE GMBH
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 OPKO HEALTH INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 ACCUQUIK TEST KITS
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.7 ACON LABORATORIES INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENTS
20.8 BIOMERIEUX SA
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 DIASORIN S.P.A
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLI0
20.9.4 RECENT DEVELOPMENTS
20.1 EUROLYSER DIAGNOSTICA GMBH
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENT
20.11 FUJIREBIO
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLI
20.11.3 RECENT DEVELOPMENTS
20.12 GENOMIC HEALTH, INC., (A SUBSIDIARY OF EXACT SCIENCES CORPORATION)
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENTS
20.13 HOLOGIC, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
20.14 HUMASIS
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 MDXHEALTHCARE
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENTS
20.16 METAMARK GENETICS, INC.
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLI0
20.16.3 RECENT DEVELOPMENTS
20.17 MYRAID GENETICS, INC.
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE ANALYSIS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENTS
20.18 PROSTATYPE GENOMICS
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 PROTEOMEDIX
20.19.1 COMPANY SNAPSHOT
20.19.2 PRODUCT PORTFOLIO
20.19.3 RECENT DEVELOPMENTS
20.2 TECO DIAGNOSTICS
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 CATEGORIZATION UNDER THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA '88) OF 1988
TABLE 2 AGE AND PROBABILITY OF DEVELOPING PROSTATE CANCER
TABLE 3 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 2019-2028 (UNITS)
TABLE 5 MIDDLE EAST AND AFRICA REAGENTS & CONSUMABLES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA INSTRUMENTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA ACCESSORIES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA CONFIRMATORY TESTSIN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA PROSTATIC ADENOCARCINOMAS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 13 MIDDLE EAST AND AFRICA SMALL CELL CARCINOMA IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA GERIATRICS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA SEVERE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA SEVERE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA LOCALIZED PROSTATE CANCER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA RECURRENT/ADVANCED PROSTATE CANCER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA BLOOD IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA TISSUE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA URINE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA HOSPITALS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA CLINICS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA CANCER RESEARCH INSTITUTES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA DIRECT TENDER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA HOSPITALS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 41 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 53 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 54 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 55 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 56 SOUTH AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 57 SOUTH AFRICA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 58 SOUTH AFRICA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 59 SOUTH AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 60 SOUTH AFRICA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 61 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 67 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 68 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 69 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 70 SAUDI ARABIA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 71 SAUDI ARABIA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 72 SAUDI ARABIA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 73 SAUDI ARABIA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 74 SAUDI ARABIA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 75 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 76 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 81 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 82 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 83 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 84 UAE PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 85 UAE CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 86 UAE IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 87 UAE MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 88 UAE BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 89 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 90 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 92 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 93 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 94 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 96 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 97 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 98 ISRAEL PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 99 ISRAEL CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 100 ISRAEL IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 101 ISRAEL MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 102 ISRAEL BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 103 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 104 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 106 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 107 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 108 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 109 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 110 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 111 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 112 EGYPT PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 113 EGYPT CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 114 EGYPT IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 115 EGYPT MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 116 EGYPT BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 117 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 118 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 119 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 120 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 121 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 122 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 123 REST OF MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
Lista de figuras
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MARKET END USERS COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 12 INCREASING PREVALENCE OF PROSTATE CANCER AND INCREASED RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTICS ARE DRIVING THE MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 14 REGULATORY FRAMEWORK FOR APPROVAL PROCESS IN CHINA
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET
FIGURE 16 ESTIMATED INCIDENCE CASES OF PROSTATE CANCER, ALL AGES
FIGURE 17 GERIATRIC POPULATION IN THE EUROPEAN REGION
FIGURE 18 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2020
FIGURE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2020-2028 (USD MILLION)
FIGURE 20 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2021-2028)
FIGURE 21 PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, 2020
FIGURE 23 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE 2020-2028 (USD MILLION)
FIGURE 24 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, CAGR (2021-2028)
FIGURE 25 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020
FIGURE 27 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 28 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 29 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2020
FIGURE 31 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP , 2020-2028 (USD MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2021-2028)
FIGURE 33 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, 2020
FIGURE 35 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, 2020-2028 (USD MILLION)
FIGURE 36 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2021-2028)
FIGURE 37 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2020
FIGURE 39 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2020-2028 (USD MILLION)
FIGURE 40 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2021-2028)
FIGURE 41 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 42 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, 2020
FIGURE 43 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, 2020-2028 (USD MILLION)
FIGURE 44 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 45 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, LIFELINE CURVE
FIGURE 46 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 47 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 48 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 49 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION, LIFELINE CURVE
FIGURE 50 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 51 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 52 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 53 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 54 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2021-2028)
FIGURE 55 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
